Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087239 | 0.84 | APLNR (0.53) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL284141 | 0.82 | APLNR (0.55) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL22018439 | 0.81 | TDP1 (0.44) | APLNRGAAKMT2AMEN1TDP1 | |
| SCHEMBL16906258 | 0.81 | APLNR (0.58) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL18476417 | 0.79 | APLNR (0.56) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL4424589 | 0.78 | APLNR (0.47) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL8842138 | 0.78 | APLNR (0.47) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL19273270 | 0.78 | APLNR (0.48) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL7052487 | 0.78 | APLNR (0.54) | APLNRGAAKMT2AMEN1MAPK1 | |
| SCHEMBL3458796 | 0.78 | APLNR (0.54) | APLNRGAAKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118955604-A | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-112004557-B | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230277677-A1 | POLYMERIC CONJUGATES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| US-11666656-B2 | Polymeric conjugates and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-06-06 | — | — | US | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2017145164-A9 | POLYMERIC CONJUGATES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2018-07-26 | — | — | WO | disclosed |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-02-01 | — | — | US | disclosed |
| WO-2017145164-A1 | POLYMERIC CONJUGATES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-08-31 | — | — | WO | disclosed |
| US-20150203634-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-07-23 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | APLNR 1967/4885GAA 2471/4885KMT2A 4385/4885 |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | APLNR 1967/4885GAA 2471/4885KMT2A 4385/4885 |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | SERPINA6, NR3C1, NR3C2 | APLNR 1967/4885GAA 2471/4885KMT2A 4385/4885 |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | APLNR 2878/4885GAA 12/4885KMT2A 3246/4885 |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | DDOST, SI, PDIA6 | APLNR 4650/4885GAA 34/4885KMT2A 4873/4885 |
| US-11666656-B2 | Polymeric conjugates and uses thereof | CD44, DCLRE1A, CD74 | APLNR 38/4885GAA 1090/4885KMT2A 1781/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | APLNR 59/4885GAA 2281/4885KMT2A 710/4885 |
| US-20230277677-A1 | POLYMERIC CONJUGATES AND USES THEREOF | CD44, DCLRE1A, CD74 | APLNR 38/4885GAA 1090/4885KMT2A 1781/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | APLNR 1967/4885GAA 2471/4885KMT2A 4385/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | APLNR 59/4885GAA 2281/4885KMT2A 710/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | APLNR 59/4885GAA 2281/4885KMT2A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.